Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies
Information source: Wayne State University
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Multiple Sclerosis
Phase: N/A
Status: Completed
Sponsored by: Wayne State University Official(s) and/or principal investigator(s): Omar Khan, MD, Principal Investigator, Affiliation: Wayne State University
Summary
The primary goal of this study will be to explore the reparative and regenerative potential
of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II
studies using conventional and non-conventional MRI sequences.
Clinical Details
Official title: An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies
Secondary outcome: Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Participating in either the CARE MS I or CARE MS II studies
Exclusion Criteria:
- Not a participant in the CARE MS I or CARE MS II studies
Locations and Contacts
Additional Information
Last updated: November 24, 2009
|